Barclays
BOLD

Barclays’s Audentes Therapeutics, Inc BOLD Stock Holding History

Barclays’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-160,578
Closed -$9.61M – 6733
2019
Q4 		$9.61M Buy
160,578
+122,192
+318% +$4.59M 0.01% 1431
2019
Q3 		$1.08M Buy
38,386
+6,861
+22% +$234K ﹤0.01% 3598
2019
Q2 		$1.19M Buy
31,525
+7,038
+29% +$270K ﹤0.01% 3501
2019
Q1 		$955K Buy
24,487
+12,523
+105% +$359K ﹤0.01% 3447
2018
Q4 		$255K Sell
11,964
-7,932
-40% -$205K ﹤0.01% 4411
2018
Q3 		$788K Buy
19,896
+15,039
+310% +$561K ﹤0.01% 3867
2018
Q2 		$186K Sell
4,857
-8,041
-62% -$298K ﹤0.01% 4782
2018
Q1 		$387K Buy
12,898
+9,763
+311% +$331K ﹤0.01% 4221
2017
Q4 		$98K Sell
3,135
-949
-23% -$26.1K ﹤0.01% 5265
2017
Q3 		$114K Buy
4,084
+3,322
+436% +$72.1K ﹤0.01% 4847
2017
Q2 		$15K Sell
762
-4,612
-86% -$73.7K ﹤0.01% 5927
2017
Q1 		$91K Buy
5,374
+4,030
+300% +$65.2K ﹤0.01% 4951
2016
Q4 		$23K Buy
+1,344
New +$23.2K ﹤0.01% 5570

Barclays's BOLD Position: Q1 2020 in Review

Barclays sold out of Audentes Therapeutics, Inc (BOLD) in Q1 2020, closing a stake of 160,578 shares — an estimated $9.61M sold.

Barclays first reported a position in BOLD in Q4 2016 and held it in 13 quarters. The position peaked at $9.61M in Q4 2019. 0 funds tracked by Wall St. Rank hold BOLD as of Q1 2020.

  • Barclays reported no remaining Audentes Therapeutics, Inc position as of Q1 2020 after selling out during the quarter.
  • Barclays sold 160,578 Audentes Therapeutics, Inc shares in Q1 2020, an estimated $9.61M.
  • Barclays first reported a position in Audentes Therapeutics, Inc in Q4 2016 and held it in 13 quarters.
  • Barclays's Audentes Therapeutics, Inc position peaked at $9.61M in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q1 2020.

Based on Barclays's 13F filing for Q1 2020, filed 13 May 2020.